KEY POINTS
- This updated American Society for Radiation Oncology (ASTRO) clinical practice guideline replaces the 2018 recommendations and addresses five clinical questions covering moderate hypofractionation (MHF), ultrahypofractionation (UHF), dose-fractionation, target volumes, and treatment techniques. It applies to definitive EBRT for localized N0M0 prostate cancer, including low-, intermediate-, high-, and very high-risk disease. Recommendations were informed by systematic evidence reviews, including 11 randomized trials involving more than 7,000 patients comparing moderate with conventional fractionation.
- Moderate hypofractionation is strongly recommended over conventional fractionation across all risk groups, supported by high-quality evidence demonstrating comparable oncological outcomes, toxicity, and quality of life. A meta-analysis cited in the guideline found a 26% relative reduction in biochemical recurrence with MHF, although some contributing trials compared biologically dose-escalated regimens. Selection of MHF should generally be independent of age, comorbidity, prostate anatomy, baseline urinary function, and the indication for androgen deprivation therapy (ADT).
- Five-fraction ultrahypofractionation is recommended as a definitive treatment option for low- and intermediate-risk disease, supported by the randomized PACE-B and HYPO-RT-PC evidence. For high- and very high-risk disease, UHF receives only a conditional recommendation based on low-quality evidence, pending mature outcomes from higher-risk trials. In patients with substantial baseline lower urinary tract symptoms, commonly corresponding to IPSS ≥15–20, MHF is conditionally preferred over UHF because of concerns about urinary toxicity.
- Preferred moderate hypofractionation schedules are 60–62 Gy in 20 fractions or 70 Gy in 28 fractions, both supported by strong recommendations and high-quality evidence. For five-fraction UHF, the guideline conditionally recommends 36.25–40 Gy in five fractions, preferably delivered on nonconsecutive days over approximately two weeks. Importantly, regimens using fewer than five fractions are strongly discouraged outside clinical trials, reflecting insufficient long-term efficacy and toxicity data.
- Elective pelvic nodal treatment requires a separate fractionation strategy. When indicated, the guideline strongly recommends MHF to the prostate with concurrent conventional or near-conventional fractionation to pelvic lymph nodes in a single-phase plan. Examples include 70 Gy in 28 fractions to the prostate with 50.4 Gy to pelvic nodes, or 60 Gy in 20 fractions to the prostate with approximately 42–44 Gy to pelvic nodes. In contrast, ultrahypofractionated elective pelvic nodal RT is conditionally recommended only within clinical trials, because randomized evidence remains insufficient.
- Target delineation and focal dose escalation are addressed explicitly. Low-risk disease generally requires prostate-only CTV coverage, while the proximal 10–20 mm of the seminal vesicles may be included for intermediate-risk disease and are recommended for high-risk disease; the entire seminal vesicles should be included when invaded. For MRI-visible dominant intraprostatic lesions, a focal boost is conditionally recommended in selected intermediate- and high-risk patients, with rectal, bladder, and urethral constraints prioritized over boost coverage. The cited FLAME trial demonstrated 86% versus 71% ten-year biochemical disease-free survival with focal boosting, although direct randomized evidence for focal boosts within MHF/UHF schedules remains unavailable.
- Daily image guidance and contemporary conformal planning remain central to safe hypofractionation. ASTRO strongly recommends daily interfraction motion management and IMRT/VMAT, while prostate MRI is recommended for UHF planning and intrafraction tracking is conditionally recommended. Typical reduced PTV margins include approximately 4–6 mm for MHF and 2–5 mm for UHF, provided that motion management supports their use. Rectal spacers are conditionally recommended after balancing modest absolute toxicity benefits against potentially serious insertion complications. No clinical advantage of proton over photon hypofractionation has been established from the available comparative evidence.
CLINICAL TAKEAWAY
The updated ASTRO guideline establishes moderate hypofractionation as the preferred definitive EBRT approach for localized prostate cancer across all risk groups, while supporting five-fraction SBRT as a standard option for low- and intermediate-risk disease. High-risk SBRT requires more selective use, elective pelvic nodal ultrahypofractionation remains investigational, and image guidance, motion management, and individual urinary symptom burden should guide treatment selection.